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Abstract
In this work, the tumor suppressor gene p16 was efficiently transferred into FR cells isolated from a patient with malignant mesothelioma
using cationic liposomes prepared from trimethyl aminoethane carbamoyl cholesterol (TMAEC-Chol) and triethyl aminopropane carbamoyl
cholesterol (TEAPC-Chol). This transfer was performed after preliminary assays were undertaken to find the optimal transfection conditions.
Results showed that an efficient transfer of plasmids containing the reporter gene pCMV-h galactosidase vectorized by TMAEC-Chol/DOPE
and TEAPC-Chol/DOPE liposomes into mesothelioma FR cells was obtained as assessed by luminometric measurements of h-galactosidase
activity. Cytotoxicity studied by MTT test showed that at concentrations used for this study, the cationic liposomes have no effect on cell
growth. Transfer into mesothelioma FR cells of a plasmid construct containing the tumor suppressor gene p16 was carried out with these
liposomes. Western blotting and immunofluorescence showed the presence of p16 in treated cells. An inhibition of cell growth was observed,
indicating that efficient tumor suppressor gene transfer can be performed by using cationic liposomes.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Malignant pleural mesothelioma (MPM) is an almost
universally fatal neoplasm that is unresponsive to current
treatment procedures including surgery, chemotherapy and
radiation therapy [1]. Because of the dismal prognosis for
patients with MPM, new treatment modalities are needed
[2,3], among them, a promising area of research is gene
therapy.
Actually, a variety of studies on tumor suppressor gene
replacement has been developed for the treatment of malig-
nancies. The association of mutated tumor suppressor genes
(p16, BRCA1, BRCA2) with diverse cancers has focused
their potential replacement with wild-type versions of sup-
pressor genes, with the same goals as any anti-cancer
therapies: selective targeting of tumor cells and optimal
therapeutic index. Among the expressed proteins, p16INK4a
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is found to be mutated or deleted in many transformed cell
lines and some primary tumors derived from multiple
human tissues, including pancreas, skin, brain, bladder, lung
and pleura [4]. p16INK4a participates in controlling the G1-S
cell cycle checkpoint through its indirect interaction with
pRb protein [5–8]. This p16INK4a gene represents a logical
candidate for tumor suppressor replacement therapy for
p16INK4a-negative tumors. In some previous papers, p16
gene transfer in mesothelioma cells has been reported.
Experiments by viral delivery have shown that the expres-
sion of the p16 protein can inhibit the progression of the cell
cycle and reduce the growth of human cancer cell lines,
including leukaemic [9] or mesothelioma cells [10].
A major problem in gene therapy concerns the method of
DNA delivery knowing that generally naked DNA does not
penetrate into cells, so a carrier is needed. In the last decade,
there were intensive investigations for the transfer of DNA
into living cells or into animal by using viral or nonviral
vectors. Viral vectors are efficient but some hazards may
exist for the host cells, then nonviral vectors appear as an
alternative [11,12].
Although generally less efficient than the viral systems in
delivery of the transgene to target cells, the main advantages
of nonviral methods include an apparent tolerance by the
immune system and less concern by safety issues. Among
the nonviral carriers, cationic lipids are the most intensively
studied, designed and tested [13–16]. By their positive
charges, cationic lipids can form complexes with negatively
charged DNA, carry the latter and help them to pass across
cell barriers. Several assays of DNA transfer in cells and in
animal models used this method [17–19].
So far, the suppressor gene p16INK4a had been transferred
using viral vectors [5,10,20,21]. The use of cationic lip-
osomes to mediate the p16 gene transfer has still been
limited. Besides the use of lipofectamine [22], one cationic
liposome has been used, not as a mere carrier but to enhance
the rate of transfection of target cells with retroviral vectors.
Porter et al. [21] complexed a virus with DC-Chol/DOPE
3h[N-(NV,NV-dimethylaminoethane)-carbamoyl]cholesterol
liposomes to transduce human mesothelioma xenografts and
found that the transfection was enhanced four- to fivefold
compared to that by the virus alone.
In this context, we used original cationic liposomes for a
transient model of p16INK4a expression in p16INK4a defective
MPM cells. Cationic lipids were synthesized with cholesterol
as the hydrophobic part, linked to the polar head by a
carbamide bond, but containing a ramified quaternary ammo-
nium polar head and different lengths of the spacer. These
cationic lipids, trimethyl aminoethane carbamoyl cholesterol
(TMAEC-Chol) and triethyl aminopropane carbamoyl cho-
lesterol (TEAPC-Chol), form with the neutral lipid dioleoyl
phosphatidylethanolamine (DOPE) very stable liposomes
with well-defined size and are able to carry oligonucleotides
or plasmids into several cell lines [23,24]. In these previous
works, the transfection level by TMAEC-Chol/DOPE lip-
osome has been compared with other carriers. For 9L and
MCF7 cell lines, comparison with other available cationic
liposomes showed that TEAPC-Chol/DOPE liposomes have
advantages compared to some known transfection reagents
[23,25]. Therefore, we propose to use these liposomes to
deliver a plasmid encoding p16 in a mesothelioma cell line.
In this work, we determined the optimal transfection con-
ditions of these cationic liposomes and tested in vitro their
ability to deliver wild-type p16 expression plasmids. We
report here the successful import of the tumor suppressor
gene p16 in a human cultured pleural mesothelioma cell line.
This successful delivery was demonstrated by the internal-
ization of p16, its functionality and its effect on the cell
proliferation. This might represent a first step for setting up
future therapy of mesothelioma using cationic liposomes.
2. Materials and methods
2.1. Materials
DOPE was obtained from Aventi-Polar Lipid (Alabaster,
AL) and used without other purification. Antibodies against
p16 were purchased from Santa Cruz Biotechnologies
(Santa Cruz, CA). For light microscopy observation, secon-
dary antibodies were labelled with fluorescein isothiocya-
nate (FITC). Reagents are analytical grade and purchased
from Aldrich, Carlo Erba and Fluka.
2.2. Cationic lipids
Cationic lipids TMAEC-Chol and TEAPC-Chol were
synthesized and characterized by Fourier transform infrared
spectroscopy (FTIR). The synthesis of these lipids was
described in previous papers [24,25].
2.3. Liposome preparation
Cationic lipids (TMAEC-Chol, TEAPC-Chol) and
DOPE in the weight ratio 1:1 were dissolved and mixed
in chloroform and the solution was dried in a rotating
evaporator. Solvent trace was removed under vacuum over-
night. The following day, sterile water (Millipore) was
added and the mixture was sonicated for 1 h in cycles of
15 min (13 min followed by 2 min rest) to clarity. The
liposome preparations were controlled by negative staining
followed by transmission electron microscopy (TEM). Their
size was characterized by quasi-elastic light scattering
(QLS). Polystyrene latex spheres of 109 nm in aqueous
solution were used for the calibration.
2.4. Plasmids
pCMV-h is a 7.2-kb plasmid encoding h-galactosidase
under the control of the cytomegalovirus promotor and was
purchased from Promega (Madison, WI). pCMV-p16, a 5.4-
kb plasmid encoding p16 under the control of the same
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promotor, was a gift of Dr. C.J. Larsen (Institut de Ge´ne´t-
ique Mole´culaire, Paris). All plasmids were conditioned in
Tris–EDTA buffer (TE), pH 8.
2.5. Formation of complexes
For complex forming, plasmid DNA (1.5 to 4.5 mg) and
cationic liposomes at desired molar charge ratios over DNA
(number of positive charges of cationic lipid per negative
charge of DNA) were separately diluted in equal volume (10
Al) of sterile water and then mixed. Complexes were formed
instantaneously after mixing and let at room temperature for
15 mn before transfection. Preliminary assays showed that
transfection of mesothelioma FR cells with cationic lip-
osomes still has small effect on the proliferation. This
protocol has been then modified to enhance the transfection
level by using spermine to condense plasmids prior to the
formation of complexes with cationic liposomes. Indeed,
this polycation is well known to condense DNA and to
enhance the transfection level [26]. Control transfection
with pCMV-hgal or pCMV-p16 precondensed by spermine
but unvectorized by cationic liposomes gave a negligible
level h-galactosidase or p16 genes. These assays indicated
that h-galactosidase activity was optimal when spermine
was added to plasmids in the ratio of 3 or 4 nmol for each
milligram of DNA before complexing with TMAEC-Chol/
DOPE or with TEAPC-Chol/DOPE liposomes, respectively.
These spermine/DNA ratios were used for complex prepa-
rations presented in the following.
2.6. Cell culture
A mesothelioma cell line, FR, was established in one of
our laboratories. It was obtained from a pleural fluid in a
patient with malignant mesothelioma. The cell line charac-
teristics were investigated by immunocytochemistry, ultra-
structural and chromosome analysis [27–29].
Cells were grown at 37 jC under 5% CO2 in RPMI 1640
L-glutamine medium (Life Technologies, Inc.), supple-
mented with fetal calf serum (10%), penicillin/streptomycin
(50 U/ml) and Hepes (10 mM). The medium was changed
twice weekly. This cell line was used between passages 7
and 21.
2.7. Transfection protocol
The day before transfection, cells were seeded onto
microscope four-well Lab-Tek plates (typically 5 104
cells/well) or onto six-well plates (5 105 cells/well). The
following day, the cells were washed, the culture medium
was removed and replaced with serum-free OPTI-MEM
(500 Al in Lab-Tek wells or 1000 Al in six wells). Plasmids
or liposome/plasmid complexes prepared in sterile water
were gently dropped for transfection. After 6 h, OPTI-MEM
was replaced with culture medium supplemented with serum
for the defined incubating time.
2.8. Transfection efficiency evaluated by X-gal test
The transfection efficiency was estimated by using
pCMV-h followed by a coloration with X-gal reagent (5-
bromo-4-chloro-3-indolyl h-D-galactopyranoside). For each
well in Lab-Tek plates, complexes of pCMV-h (3 Ag) and
liposomes (18 nmol) were used. The X-gal test was per-
formed after 48 h of incubation. For this, the cells were
washed with PBS solution and fixed in 1% formaldehyde,
0.2% glutaraldehyde, in phosphate buffer saline (PBS), for 2
min. After washing twice with PBS, the X-gal solution (1
mg/ml X-gal, 5 mM potassium ferrocyanide, 5 mM potas-
sium ferricyanide, 1 mM MgCl2 in PBS) was added and the
cells were incubated for a further 12 h before microscopic
observation. The transient transfection efficiency was esti-
mated by the percentage of blue-stained cells over the total
number of cells.
2.9. Transfection level
The level of the transfection was estimated by measuring
the quantity of the expressed protein. Cells were seeded in
six-well plates and the chemiluminescence of h-gal was
measured 48 h after transfection in the presence of the
substrate 3-4(-methoxyspiro[1,2-dioxetane-3,2V-tricy-
clo(3.3.1.1)decane]-4-yl)phenyl-h-D-galactopyranoside
(APMGD) by using the Tropix kit Galactolight Plus (Tro-
pix, Bedford, MA). Following the procedure of the supplier,
after lysing the cells, 20 Al of the extract was incubated with
200 Al of the reagent (diluted to 1%). After 1 h, 300 Al of
the accelerator was added and luminometric measurement
was made using a BCL luminometer (Gouteyron, Val le
Puy, France). Protein was titrated by using a Bio-Rad kit in
order to normalize the transfection level and expressed in
relative light units (RLU) per milligram of total protein.
2.10. Western blot analysis
Cells were grown in the presence of pCMV-p16/liposome
complexes in six-well plates. After 24 or 48 h, cells were
detached using a nonenzymatic cell dissociation solution
(Sigma) and treated with cold lysis buffer (50 mM Tris–
HCl pH 7.5, 250 mM NaCl, 5 mM EDTA, 0.1% Nonidet P-
40, 50 mM NaF, 1 mM PMSF, 1 mM NaHCO3, pH 8)
containing antiproteases cocktail. The protein concentrations
were measured by BSA protein assay kit quantification (Bio-
Rad, Hercules, CA) and standardized by adjusting lysis buffer
volumes. Fifty microliters per lane were separated by 10%
SDS-PAGE and trans-blotted onto nitrocellulose membrane
(Schleicher and Schull, Dassel, Germany) for p16. Nitro-
cellulose filters were blocked for 1 h using 5% fat dry milk in
1 PBS. The membranes were incubated with anti-p16
antibodies diluted at 1:2500 in PBS containing 0.5% Tween
20 (PBS-T) for 1 h. After three washes in PBS-T, membranes
were incubated with horseradish peroxidase-conjugated don-
key anti-mouse diluted at 1:10000, followed by development
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with an enhanced chemiluminescence Western blot detection
kit ECL (Amersham, Buckinghamshire, UK).
As positive control for p16INK4a, HBL100 cells (human
normal breast cell line) have been used and untransfected
FR cells were taken as negative control.
2.11. Immunofluorescence localization of p16
Transfected and untransfected cells were grown in four-
well Lab-Tek plates (Nalgen Nunc, Napperville, IL). After
24 or 48 h, cells were washed three times with PBS, followed
by fixation in acetone for 10 min. After rehydration, the
nonspecific sites were blocked for 30 min with PBS con-
taining 0.1% BSA. The cells were then incubated for 1 h with
anti-p16 diluted at 1:25 in PBS. The plates were washed
again and incubated for 1 h with FITC-conjugated secondary
antibodies (Immunotech, Marseille, France) diluted 1:20 in
PBS. After additional washing, the plates were mounted
using Mowiol (Calbiochem, La Jolla, CA) and then visual-
ized using a Reichert fluorescence microscope.
2.12. Cytotoxicity
Cellular toxicity was investigated by studying the viabil-
ity of cells, using the MTT method. Cells were seeded in 96-
well plates. After defined times in the presence or not of
TMAEC-Chol/DOPE and TEAPC-Chol/DOPE liposomes,
cells were washed twice with PBS and then 100 Al of RPMI
medium supplemented with 10% serum and containing 1
mg/ml MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tet-
razolium bromide] was added. The coloration was performed
after 4-h incubation, cells were lysed with dimethylsulfoxide
(DMSO) and the optical density at 570 nm of the solution
was read by a Bio-Rad plate Reader (Model 450).
2.13. Cell proliferation assay
In order to determine the effect of restoration of p16 on
cell proliferation, cell growth was investigated after trans-
fection. FR cells in 10% FCS/RPMI were seeded into T25
tissue culture plates at a density of 3 105 cells/plate
(Falcon, Strasbourg, France) and allowed to adhere to the
plastic for 24 h. Cells were then transfected following the
protocol described above. After the desired time (3, 6, 9
days), they were washed with PBS, dissociated with 0.025%
trypsin–EDTA (Life Technologies) and counted using a
Coulter counter (Coultronics, Margency, France).
3. Results
3.1. Characterization of TMAEC-Chol/DOPE and TEAPC-
Chol/DOPE liposomes
Liposomes prepared from TMAEC-Chol (or TEAEC-
Chol) lipid and DOPE were previously characterized by
QLS and TEM as described previously [23,31]. Electron
microscopy showed that liposomes are unilamellar vesicles
and QLS indicated a monomodal distribution of size with
the mean value of 124 and 104 nm for, respectively,
TMAEC-Chol/DOPE (1:1) and TEAPC-Chol/DOPE (1:1)
liposomes in water. The polydispersity factors were 0.33
and 0.23, respectively. The liposome size was practically
independent on the preparation conditions; there is only a
small difference in these characteristics from one prepara-
tion to another, and liposomes were very stable, preserved at
many months without noticeable alteration in size distribu-
tion.
3.2. Characteristics of the FR cell line
Characteristics of FR cells were previously investigated
[26–28]. This cell line exhibited the characteristics of
mesothelial cells as determined by immunocytochemistry
and ultrastructural studies. Cells coexpressed cytokeratin
and vimentin, but no CEA expression was found. Ultra-
structural features agreed with the typical characteristics of
mesothelial cells, which are occurrence of desmosomes,
long and slender microvilli and perinuclear organization of
intermediate filaments. Cells were hyperdiploid since 64%
of the metaphases contained between 51 and 75 chromo-
somes per metaphase. The remaining metaphases were
tetraploid or nearly tetraploid.
3.3. Cytotoxicity study
The cytotoxicity of TMAEC-Chol/DOPE liposome and
TEAPC-Chol/DOPE liposome was determined with the
MTT assay. Fig. 1 represents the viability of mesothelioma
FR cells incubated with and without cationic liposomes as a
Fig. 1. Dose-dependent viability of mesothelioma FR cells transfected with
TMAEC-Chol/DOPE and TEAPC-Chol/DOPE liposomes after 48 h of
incubation. Percentage of viable cells was obtained by MTT assay as
described in Materials and methods and referred to the viability of control
cells taken as 100%.
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function of the cationic lipid concentration. From these
plots, the concentration corresponding to half the maximum
growth TC50 was estimated to be 70 AM for TEAPC-Chol/
DOPE liposomes. This TC50 is slightly higher for TMAEC-
Chol/DOPE liposomes. With the cationic lipid/DNA molar
charge ratio X = 2, this would allow the use of TMAEC-
Chol/DOPE and TEAPC-Chol/DOPE liposomes to trans-
port plasmids up to DNA concentration of 35 AM (in
nucleotides).
3.4. Transfection efficiency with plasmids vectorized by
TMAEC/DOPE and TEAPC/DOPE liposomes
The transfection efficiency evaluated by the test X-gal
can be seen in Fig. 2. The blue-colored cells, indicating the
presence of expressed h-galactosidase, were observed by
light microscopy and counted. Controls of endogenous h-
galactosidase and the effect of the liposome carrier were
evaluated using untransfected cells (Fig. 2A) which do not
show any detectable blue spot. Very few blue-stained cells
were observed after transfection with of unvectorized plas-
mids (Fig. 2C). With the same amount of DNA carried by
TMAEC-Chol/DOPE liposomes, the efficiency of the trans-
fection for mesothelioma FR cells can reach 70% (Fig. 2B).
3.5. Transfection level
The results on transfection level, estimated by lumino-
metric measurements of expressed h-gal, are shown in
Fig. 3. For this purpose, the total chemiluminescence
intensity (in RLU), including that of endogenous h-gal,
was measured. The endogenous h-gal, estimated from the
intensity due to the untransfected cells, was then suppressed
and the results were normalized for every milligram of total
protein.
In these assays, we have explored the effect of the molar
charge ratio cationic lipid/DNA and found that the optimal
level was observed when the molar charge ratio cationic
Fig. 2. Transfection efficiency of plasmid pCMV-h delivered into FR mesothelioma cells by TMAEC/DOPE liposomes. Staining was obtained with X-gal
assay 48 h after transfection. (A) Untransfected cells. (B) Cells transfected with pCMV-h vectorized by TMAEC-Chol/DOPE liposomes. (C) Cells transfected
with free pCMV-h.
Fig. 3. Transfection level of plasmid pCMV-h precondensed with spermine
(3 nmol/mg DNA) delivered into FR cells by cationic liposomes TMAEC-
Chol/DOPE (1:1) and TEAPC-Chol/DOPE (1:1), evaluated by h-gal
activity 48 h after transfection. The effects of the lipidic nature and of the
molar charge ratio cationic/DNA are shown. Cells: 5 105/well. Trans-
fection medium for the first 6 h: OPTIMEM without serum. After 6 h,
OPTIMEM was replaced with the serum-containing culture medium RPMI
1640. (1) Cells transfected with unvectorized pCMV-h. (2) Cells
transfected with TMAEC-Chol/DOPE carrying 1.5-Ag pCMV-h, X = 2.
(3) and (4): with the same liposome carrying 3-Ag pCMV-h, charge ratios
X = 2 and X = 4, respectively. (5) and (6): with TEAPC-Chol/DOPE
liposomes carrying 1.5- and 3-Ag pCMV-h, respectively; charge ratio X = 2.
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lipid/DNAwas X = 2. For comparison, we present the trans-
fection levels in mesothelioma FR cells when TMAEC-Chol/
DOPE and TEAPC-Chol/DOPE were used. Fig. 3 shows that
the transfection level of TMAEC-Chol/DOPE is higher than
that of TEAPC-Chol/DOPE liposomes.
3.6. Delivery and persistence of gene p16 observed by
immunofluorescence
Mesothelioma cells transfected with pCMV-p16 plasmids
complexed with TMAEC-Chol/DOPE and TEAPC-Chol/
Fig. 4. Transfer of p16 into mesothelioma cells FR, observed by immunofluorescence using antibodies against anti-p16, labelled with fluorescein. Cells were
transfected in OPTIMEM with pCMV-p16 complexed with cationic liposomes for 24 h. (A) Control untransfected cells FR. (C) Control FR cells transfected
with pCMV-p16 unvectorized by liposomes. (E) FR cells transfected with pCMV-p16 complexed with TMAEC-Chol/DOPE liposomes. (G) FER cells
transfected with pCMV-p16 complexed with TEAPC-Chol/DOPE liposomes. Amount of plasmids: 3 Ag. Molar charge ratio cationic lipid/DNA: X = 2. (B, D,
F, H): same fields observed with DAPI staining.
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DOPE liposomes are illustrated in micrographs of Fig. 4.
Untransfected cells did not show any presence of p16,
indicating that mesothelioma FR cells do not express p16
(Fig. 4A). Cells transfected with unvectorized pCMV-p16
showed only low level of p16 in the nucleus (Fig. 4C)
whereas cells transfected with pCMV-p16 vectorized by
TMAEC-Chol/DOPE and TEAPC-Chol/DOPE cationic lip-
osomes showed higher labelling (Fig. 4E and G, respec-
tively). Comparison with cells stained with DAPI, a nuclear
staining (Fig. 4B, D, F, H), shows that the expression was
rather nuclear. The fluorescence is only slight, diffuse in the
cytoplasm and much more intense in the nucleus as
expected. It seems that there is slightly more expression of
p16 with TEAPC-Chol/DOPE liposomes than with
TMAEC-Chol/liposomes. These observations were con-
firmed by Western blot analysis. Pictures made after 24
and 48 h showed that the expression of p16 was maintained
at 48 h (data not shown).
3.7. 16INK4 expression observed by Western blotting
In order to assess the efficiency of the transfer of p16 by
using cationic liposomes TMAEC-Chol/DOPE and
TEAPC-Chol/DOPE, we have undertaken Western blot
analysis. The results are given in Fig. 5. In the left lane of
Fig. 5A, a positive control was made with HBL100 cells
where a large amount of p16 was found, confirming the high
level of expression in this cell line [5]. Negative control was
obtained with untreated FR cells (right lane C) where p16
was not detected. On the contrary, the presence of p16 was
observed in middle lanes with cells treated with TMAEC-
Chol/DOPE liposomes and TEAPC-Chol/DOPE liposomes,
indicating the efficiency of the transfection. Fig. 5B shows
that the transfer of p16 is dose-dependent and the expression
of p16 was slightly higher when TEAPC-Chol/DOPE lip-
osomes were used than with TMAEC-Chol/DOPE lipo-
somes. Fig. 5B reveals also that p16 was still observed 48
h after transfection.
3.8. Dose and time effect on proliferation of transfected FR
mesothelioma cells
The functionality of delivered p16 in mesothelioma FR
cells was investigated by proliferation assay. Cells treated
with pCMV-p16 have been counted 3 days after the trans-
fection. Data are given in Fig. 6. With 3, 5 or 8 Ag of
pCMV-p16, we observed an effect of 16%, 20% and 34%,
respectively, on the inhibition of cell proliferation. More-
over, with the dose of 8 Ag of pCMV-p16, the effect on cell
growth was followed in time, by counting cells 3, 6 and 9
days after the transfection as indicated in Fig. 7. In first
experiments, cells were transfected one time with 8 Ag of
pCMV-p16. An inhibition of proliferation of about 34% was
observed after 3 days. However, after 6 days the prolifer-
ation reached the control level as indicated by the dashed
plots. In the second experiments, cells were administered
again with the same amount of pCMV-p16 after 3 and 6
days. In this case, an inhibition of 50% at day 6 and another
of 63% were observed at day 9 for TMAEC-Chol/DOPE
liposomes (solid plots). A similar but slightly smaller effect
of 45% at day 6 and 53% at day 9 was obtained with
TEAPC-Chol/DOPE liposomes. It is to note that in these
assays, results were obtained by comparison to the controls
           
Fig. 5. Western blot analysis of pCMV-p16 transfer into FR mesothelioma
cells by cationic liposomes TMAEC-Chol/DOPE and TEAPC-Chol/DOPE.
(A) Expression of the suppressor gene p16. The positive control was
indicated by the spot in lane 1 obtained with endogenous p16 of
untransfected mammary carcinoma HBL 100 cells (left lane). The negative
control was indicated by the right lane C obtained with untransfected FR
cells. The two middle lanes respectively show the expression of exogenous
p16 introduced by TMAEC-Chol/DOPE and TEAPC-Chol/DOPE lip-
osomes. (B) Effect of the incubation time (24 or 48 h), of the DNA amount
(1.5 or 3 Ag) and of the nature of cationic lipid (TMAEC-Chol or TEAPC-
Chol).
Fig. 6. Dose effect on proliferation inhibition of mesothelioma cells
transfected by pCMV-p16 complexed with cationic liposomes TEAPC-
Chol/DOPE (.) and TMAEC-Chol/DOPE (n). pCMV-p16 and cationic
liposomes were complexed in the molar charge ratio cationic lipid/DNA,
X = 2. Results were obtained at day 3, with three sets of measurements in
duplicate. Cell number of control untreated cells was taken as 100%.
S. Piperno-Neumann et al. / Biochimica et Biophysica Acta 1611 (2003) 131–139 137
obtained with untreated cells and cells incubated with lip-
osomes alone or with plasmid alone. Moderate concentra-
tions of liposomes alone slightly enhance cell growth and no
change was observed with plasmid alone. So, the prolifer-
ation inhibition observed is only due to pCMV-p16 deliv-
ered by liposomes. This is clearly a proof of the ability of
TMAEC-Chol/DOPE and TEAPC-Chol/DOPE liposomes
to efficiently deliver cancer suppressor gene p16.
4. Discussion
The results of this work showed that the tumor suppres-
sor gene p16 could be transferred using cationic liposomes
into FR cells deficient in p16INK4a expression.
To define the best conditions for gene transfer, we
investigated the transfection efficiency with two different
formulations of liposomes and DNA/liposome complexes.
When evaluating the activity of the reporter gene encoding
the h-galactosidase, results indicate that TMAEC-Chol/
DOPE and TEAPC-Chol/DOPE liposomes are efficient to
carry DNA plasmids into FR cells.
The most important finding is the transfer of tumor
suppressor gene p16INK4a in cells by using cationic lipids.
The cellular expression of the transgene p16 was demon-
strated by immunofluorescence and Western blot. The
protein coded by the transgene was strongly expressed in
the nucleus and slightly in the cytoplasm as attested by a
pattern that was much more fluorescent inside than outside
the nucleus. Moreover, the nuclear fluorescence was diffuse
and not punctate, suggesting that the protein is not located in
limited areas of the nucleus. A slight difference between the
expression profiles of the reporter gene and the p16 gene is
observed. This could be explained by the fact that there is a
difference in size of plasmids pCMVh (7 kb) and pCMV-
p16 (5 kb), which implies a difference in the number of
plasmid copies corresponding to the same amount of DNA
delivered. Therefore, the number of p16 gene copies is
greater than that of h-gal gene. Moreover, this may due
also to the fact that cytoenzymatic techniques, such as the
X-gal assay used here, are not as sensitive as immunocyto-
logical methods [30].
From our results, if TMAEC-Chol/DOPE and TEAPC-
Chol/DOPE are both able to deliver plasmids in mesothe-
lioma FR cell, the efficiency and the resident time of DNA
slightly depend on the nature of the cationic lipid. The
difference between TMAEC-Chol and TEAPC-Chol stands
in the structure of their cationic polar heads. This depend-
ence on the nature of the carriers can be explained by the
binding of DNA to the lipid molecules. A stronger binding
is necessary to form the complex whereas a weaker is
needed to release DNA in the cellular compartment. The
resident time is an interesting characteristic of the trans-
fection. With the cationic liposomes used here, immuno-
fluorescence indicates that the resident time is at least 48 h.
Such a relatively long time may be important for a gene
therapy modality, although its lifetime is limited as shown
by the proliferation assay.
The functionality of the delivered gene was assessed by
the effect on cell proliferation. Three days after transfection,
a dose-dependent effect was already observed as indicated
by Fig. 6. An inhibition of about 30% was obtained in cells
incubated with 8 Ag of pCMV-p16. This inhibition was only
transient because the cell growth took place again and
attained the level of the control after 6 days. However, with
repeated doses, the inhibition was maintained and reached
about 50% and 63% after 6 and 9 days, respectively. This
inhibition effect agreed with the deficiency of p16 in the
studied FR cells, for which the delivery of p16 prevented
cell growth. This inhibition rate is in the same order with
that observed by Frizelle et al. [10] on cells incubated with
p16 gene delivered virally. It is worth noting from the results
of cytotoxicity study that the IC50 of cationic lipid concen-
tration is about 70 AM, corresponding to 35 AM in nucleo-
tide so that in the range of used concentrations (8-50 AM in
cationic lipid), liposomes alone were not cytotoxic. This
allowed repeated administrations of p16 gene in order to
maintain its inhibition effect on cell growth.
It is also important to note some other advantages in the
use of cationic liposomes prepared with TMAEC-Chol and
TEAPC-Chol lipids. As shown from previous works, they
are prefabricated, very stable and have well-defined sizes.
Moreover, they are able to form complexes with oligonu-
cleotides or plasmids and can be mixed with any desired
DNA before transfection. With these lipids, it is easy to
obtain the complexation with DNA with high yield which
can reach 100% [31]. This lipid-mediated gene transfer is
relatively nontoxic and nonimmunogenic. Consequently,
Fig. 7. Proliferation inhibition of mesothelioma cells under the effect of
pCMV-p16 delivered by cationic liposomes TMAEC-Chol/DOPE and
TEAPC-Chol/DOPE. (E) Untreated cells; (n) cells transfected with
pCMV-p16/ (TEAPC-Chol/DOPE) complexes; (.) cells transfected with
pCMV-p16/(TMAEC-Chol/DOPE) complexes. Dashed lines: cells treated
with one dose at day 0. Solid lines: cells treated with one dose at day 0 and
with repeated doses at day 3 and day 6. Complexes were prepared with 8-Ag
pCMV-p16 and TMAEC-Chol/DOPE or TEAPC-Chol/DOPE liposomes in
the molar charge ratio cationic lipid/DNA, X= 2. Results were obtained
with three sets of measurements in duplicate. Cell number of control
untreated cells was taken as 100%.
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cationic liposomes may permit multiple administrations of
the gene of interest, which is likely to be necessary for the
successful treatment of advanced tumors [18].
It must be emphasized that p16INK4a is an important
protein to be considered in cancer therapy, regarding its role
in the control of cell proliferation, especially as an inhibitor
of pRb phosphorylation. In many types of tumor, besides
MPM, disrupted pRb function seems related to p16INK4a
inactivation rather than to pRb alteration [10,22,32–34].
Reexpression of p16INK4a by gene transfer in p16-deficient
tumor cells has been found to restore pRb functionality
[10,22], suggesting that p16INK4a might play a role in the
treatment of cancer cells using gene therapy. Transfer of a
suppressor gene such as p16 can also be used for other types
of cancer cells derived from various human tissues, includ-
ing pancreas, skin, brain, bladder and lung [5]. A summary
on the frequency of p16 inactivation in several primary
tumours has been reviewed by Liggett and Sidransky [35]
and Ruas and Peters [6], in particular the implication on
mesothelioma frequently associated with asbestos exposure.
Now, most experimental studies have used viral carriers
for gene transfer mainly because of the better efficiency of
viruses to achieve gene transfer in comparison with nonviral
vectors. However, there is some reluctance to use viral
vectors, regarding an insert size limit or its hazards for the
host such as stimulation of the immune system or possibility
of oncogenic risks. Therefore, the development of nonviral
methods is needed. In the present study, using original
TMAEC-Chol/DOPE and TEAPC-Chol/DOPE cationic lip-
osomes with low cytotoxicity, we demonstrated an efficient
gene transfer in a human mesothelioma cell line.
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